Which blood tests should be ordered to rule out inflammatory bowel disease?

Blood Work to Rule Out IBD

Order a combination of fecal calprotectin (>150 mg/g cutoff), CRP (>5 mg/L cutoff), complete blood count (hemoglobin and platelet count), and albumin to effectively rule out inflammatory bowel disease. 1, 2

Recommended Laboratory Testing Algorithm

First-Line Tests (Order Together)

Stool Tests:

• Fecal calprotectin (cutoff ≥150 mg/g) - This is the single most valuable non-invasive test for IBD screening 1, 2
• Stool culture and C. difficile testing to exclude infectious causes 2

Blood Tests:

• C-reactive protein (CRP) (cutoff >5 mg/L) 1, 2
• Complete blood count with attention to:
  • Hemoglobin (anemia suggests active inflammation) 3
  • Platelet count (thrombocytosis indicates inflammation) 3
• Albumin (hypoalbuminemia suggests chronic inflammation) 3
• Erythrocyte sedimentation rate (ESR) 3

Test Performance and Interpretation

Optimal Screening Strategy

The combination of symptoms + blood markers + fecal calprotectin provides the highest diagnostic accuracy (AUC 0.997) 4. This approach outperforms using any single test or combination of two tests.

Specific Test Combinations by Clinical Context

For ruling OUT IBD (high negative predictive value):

• Normal fecal calprotectin (<150 mg/g) + normal CRP (<5 mg/L) + normal hemoglobin effectively rules out IBD 1, 2, 5
• The combination of hemoglobin and platelet count alone provides 90.8% sensitivity and 80% specificity 3

For ruling IN IBD (high positive predictive value):

• Elevated fecal calprotectin (>150 mg/g) OR elevated CRP (>5 mg/L) in symptomatic patients suggests active inflammation 1, 2
• Combining abnormal hemoglobin with abnormal platelet count yields 94.4% positive predictive value 3

Critical Caveats and Pitfalls

Important Limitations to Recognize

1. Biomarkers can be falsely elevated: CRP, fecal calprotectin, and fecal lactoferrin may be elevated from non-intestinal sources of infection or inflammation 2. Always exclude infectious causes first.

2. Disease extent affects accuracy: Biomarkers are less accurate in detecting inflammation in ulcerative proctitis or limited segmental disease 2. They may miss mild endoscopic activity (Mayo Endoscopic Score 1) 2.

3. Normal biomarkers don't completely exclude IBD: In patients with typical IBD symptoms but normal biomarkers, endoscopic assessment remains necessary 1, 2. Approximately 10-25% of IBD patients may have normal inflammatory markers 3, 6.

4. Fecal calprotectin outperforms CRP: Calprotectin shows consistently better sensitivity and specificity (0.61-1.0 and 0.71-1.0, respectively) compared to CRP alone 6. When resources are limited, prioritize fecal calprotectin over CRP.

When Endoscopy is Still Required Despite Blood Work

Based on AGA guidelines 1, 2:

• Mild symptoms with elevated biomarkers → Proceed to endoscopy before treatment adjustment
• Mild symptoms with normal biomarkers → Proceed to endoscopy (biomarkers may miss mild disease)
• Moderate-to-severe symptoms with normal biomarkers → Proceed to endoscopy (high clinical suspicion overrides negative biomarkers)
• Moderate-to-severe symptoms with elevated biomarkers → May treat empirically without endoscopy

Practical Implementation

For a patient presenting with chronic diarrhea, abdominal pain, or other IBD-suspicious symptoms:

1. Simultaneously order: Fecal calprotectin, CRP, CBC (with differential), albumin, ESR
2. Add stool studies: Culture, ova and parasites, C. difficile
3. Interpret results:
   • If fecal calprotectin <150 mg/g AND CRP <5 mg/L AND normal hemoglobin/platelets → IBD unlikely (NPV ~90%) 4, 5
   • If fecal calprotectin ≥150 mg/g OR CRP ≥5 mg/L OR anemia/thrombocytosis → IBD possible, proceed to endoscopy
   • If high clinical suspicion persists despite normal labs → Proceed to endoscopy regardless 1, 2

The combination approach using symptoms, blood markers (hemoglobin, platelets, CRP, albumin), and fecal calprotectin will correctly identify approximately 97% of IBD cases while avoiding unnecessary endoscopy in patients without disease 4.